Two abstracts accepted for oral presentation
at the 13th London International Cough Symposium
NEW
HAVEN, Conn., July 2, 2024
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for the
treatment of chronic cough in idiopathic pulmonary fibrosis (IPF)
and refractory chronic cough (RCC), today announced
that senior management will be attending investor and medical
conferences in July and August. In addition, Trevi is pleased to
announce that abstracts on the ongoing Phase 2b CORAL and Phase 2a RIVER trials were accepted
for presentation at the Thirteenth London International Cough
Symposium.
Leerink Partners Therapeutics Forum: I&I and
Metabolism
July 9-10, 2024,
Boston, MA
Trevi Representatives: Jennifer Good, President and
CEO, and Lisa Delfini, CFO
The Thirteenth London International Cough
Symposium
July 18-19, 2024,
London, UK
Abstract 1: Sample Size Reestimation in an Ongoing
Dose-ranging Study of Nalbuphine Extended-release For Cough in
Idiopathic Pulmonary Fibrosis (CORAL)
Abstract 2: Efficacy And Safety of Nalbuphine
Extended-release Tablets for the Treatment of Refractory Chronic
Cough: A Phase 2 Trial in Progress (RIVER)
Symposium Focus: The Thirteenth London International Cough
Symposium brings together clinicians, scientists, and researchers
in the field of cough from across the world. The purpose of this
symposium is to share, review and discuss emerging ideas, novel
approaches, and clinical research advancements in the management of
chronic cough.
Registration details
Oppenheimer's Biotech in the Berkshires
August 5-7, 2024, Lenox, MA
Trevi Representative: Jennifer
Good, President and CEO
Stifel 2024 Biotech Summer Summit
August 12-14, 2024, Newport RI
Trevi Representatives: Jennifer
Good, President and CEO, and Farrell Simon, CCO
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for the treatment of chronic cough in idiopathic
pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Haduvio is a dual ĸ-opioid receptor agonist and µ-opioid receptor
antagonist that works both centrally in the brain as well as
peripherally in the lungs and has the potential for a synergistic
antitussive effect to treat chronic cough.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. In IPF, chronic cough may lead to worsening disease and may
be associated with a higher risk of progression, death, or need for
lung transplant. There are no approved therapies for the treatment
of chronic cough in IPF and current treatment options provide
minimal relief to patients. RCC affects up to 10% of the adult
population, and Haduvio's expansion into RCC has the potential to
reach patients suffering from moderate to severe chronic cough.
There are also no approved therapies for RCC in the US.
Parenteral nalbuphine is not scheduled by the U.S. Drug
Enforcement Agency. Trevi intends to propose Haduvio as the trade
name for oral nalbuphine ER. Its safety and efficacy have not been
evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-investor-and-healthcare-events-302187587.html
SOURCE Trevi Therapeutics, Inc.
